Business Context and Reporting Period
Compugen Ltd. (NASDAQ: CGEN) filed a Form 6-K on February 9, 2006, reporting financial results for the fourth quarter and full year ended December 31, 2005. The company is transitioning from a life science software provider to a biotechnology discovery firm focused on licensing therapeutic and diagnostic product candidates under milestone and revenue-sharing agreements.
Key Financial Metrics
| Metric | Q4 2005 | Q4 2004 | Full Year 2005 | Full Year 2004 |
|---|---|---|---|---|
| Revenues | $0 | $159,000 | $646,000 | $2,630,000 |
| Net Loss | $3,347,000 | $3,743,000 | $13,978,000 | $13,722,000 |
| Net Loss Per Share | ($0.12) | ($0.14) | ($0.50) | ($0.50) |
| Governmental Grants (R&D Deduction) | $800,000 | $393,000 | $2,254,000 | $1,397,000 |
| Cash and Equivalents (Year-End) | Total: $36.8 million (includes $834k held for partners) |
Liquidity and Debt: As of December 31, 2005, total current assets were $32.5 million against current liabilities of $3.7 million. The company reported no long-term debt, though it carries accrued severance pay of $1.7 million.
Material Changes vs. Prior Period
- Revenue Decline: Full-year 2005 revenues dropped 75% to $646,000 from $2.63 million in 2004, driven by the cessation of fee-based software services. Q4 2005 revenues were zero compared to $159,000 in Q4 2004.
- Expense Reclassification: Governmental and other grants were reclassified from revenue to a deduction from research and development (R&D) expenses. This adjustment increased reported R&D expenses net of grants to $10.4 million for 2005.
- Loss Stability: Despite the revenue drop, the full-year net loss remained relatively flat at approximately $14.0 million, similar to the $13.7 million loss in 2004.
- Cash Position: Cash, cash equivalents, and marketable securities increased to $36.8 million at year-end 2005 from $20.6 million in 2004 (excluding the $834k held for partners).
Guidance, Outlook, and Risks
2006 Objectives: Management aims to increase the number of product candidates under licensing agreements. The Diagnostic Unit will expand into nucleic acid diagnostics, while the Therapeutics Unit plans to complete experimental validation of candidates and seek partners for commercialization.
Cash Flow Guidance: The company projects net cash usage for 2006 to be in the range of $11 million to $13 million. Based on current balances, Compugen expects to end 2006 with approximately $24 million in cash.
Risks: Forward-looking statements are subject to risks including changes in collaborator relationships, competitive product impacts, and the ability to implement technological improvements. The company's primary financial risk is the need to secure resources to continue development until positive cash flow is achieved.
Investor Verification Checklist
- Verify the sustainability of the $11-13 million projected cash burn rate for 2006.
- Confirm the status of milestone and royalty agreements with the three diagnostic partners mentioned.
- Monitor the timeline for selecting therapeutic candidates for further development and subsequent partner identification.
- Review the reclassification of governmental grants to ensure accurate comparison of R&D efficiency year-over-year.
- Assess the $834,000 held for research consortium partners to confirm it is not available for general corporate use.